A neutral, evidence-rated side-by-side of Testolone (RAD-140) and Ligandrol (LGD-4033). Figures are typical reference values, not recommendations.
| Testolone (RAD-140) | Ligandrol (LGD-4033) | |
|---|---|---|
| Type | SARM | SARM |
| Evidence level | Limited | Emerging |
| Primary class | Non-steroidal | Non-steroidal |
| Half-life | ~60 hours (estimated) | ~24-36 hours |
| Typical dose | 10–20 mg/day | 5–10 mg/day |
| Aromatises | No | No |
| Hepatotoxicity | Moderate | Low |
| HPTA suppression | Severe | Moderate |
| Documented effects | 3 | 2 |
| Documented side effects | 3 | 3 |
Testolone (RAD-140) is a potent non-steroidal SARM originally explored for breast cancer and muscle wasting. Human data are minimal, limited largely to an early oncology trial, so most claims are preclinical or anecdotal. Recreational users report strong strength and size gains alongside marked testosterone suppression, and case reports link it to liver injury.
Full Testolone (RAD-140) page →Ligandrol (LGD-4033) is a non-steroidal SARM with higher potency than ostarine, studied in small Phase I trials for safety and lean-mass effects. It is popular in anecdotal recreational use for strength and size but reliably suppresses testosterone even at low milligram doses. It is unapproved, prohibited in sport, and linked to case reports of liver injury.
Full Ligandrol (LGD-4033) page →